| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_94790bb32f786ed05859a38b9500c01e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b0f7c1fae45fe0a5988a9d4d48bc4bfc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_aa48a431ce250933eb0fdd7a1caf3f30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9077ead1ebd785c9b654725f182bee40 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-573
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-337
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-13
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4706
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-19
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-127
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4196
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7048
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7072
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7012 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-19
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-127 |
| filingDate |
2005-10-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9f5c8fa2b47d103c5707c9b1dc8b9bea
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d13b710e10a98fe574cb5538f5a19f55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b9152f2a42aed42b0a46856252a0d162 |
| publicationDate |
2006-05-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2006050327-A2 |
| titleOfInvention |
Lyophilized liposome formulations and method |
| abstract |
Formulations and methods for preparing a lyophilized composition comprising liposomes comprised of an unsaturated lipid and a hydrophobic drug associated with the liposome, and a cryoprotectant in a solution at a selected concentration. The phase transition temperature of the lipid is greater than the freezing point of the solution at the selected concentration. Preferably the lipid is palmitoyl-oleoylphosphatidylcholine and the cryoprotectant is sucrose. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10300018-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2641605-C2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108272759-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10413511-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11737982-B2 |
| priorityDate |
2004-10-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |